IMR Press / RCM / Special Issues / pharmacological_treatments_of_ACS_2

Advances in Pharmacological Treatments of Acute Coronary Syndromes - version 2.0

Submission deadline: 30 April 2024
Special Issue Editor
  • Pietro Scicchitano, MD, PhD
    Department of Cardiology – Hospital “F. Perinei”, Altamura (BA), Italy
    Interests: cardiovascular pharmacology; acute coronary syndrome; chronic coronary syndrome; secondary prevention; anticoagulants; antiplateletes; vascular biology; biomarkers; heart failure
    Special Issues and Topics in IMR Press journals
Special Issue Information

Dear Colleagues,

Acute coronary syndromes (ACS) are the leading cause of death worldwide. The development of percutaneous treatment options dramatically improves the outcome of ACS and of ACS-related consequences. The introduction of novel pharmacological treatments have been introduced on parallel to the performance of invasive procedures. For example, novel insights into antiplatelet treatments have improved the performance of stent implantation and reduced the ACS consequences on the heart. Lipid management in the acute setting is facing a new era which is based on the need to target specific proteins able to counteract the action of lipid molecules in myocardial infarction and to prevent short-, mid- and long-term atherosclerotic alterations in coronary vessels. Advances in the knowledge of biochemical pathways mainly related to atherosclerotic plaque instability and progression forced scientific community to develop pharmaceutical compounds able to acutely block the inflammation of the vessels which is mainly responsabile for the acute and chronic progression of atherothrombosis.

The aim of this Special Issue is to collect high-quality original research papers and comprehensive reviews on recent advances in the pharmacological treatment of acute coronary syndromes in order to provide deeper insights into this ongoing topic.

Pietro Scicchitano
Guest Editor

acute coronary syndrome
cardiovascular pharmacology
target therapies
vascular biology
advances in therapies
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.

Back to top